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background:  According to a non-randomized comparison, higher acute recoil has been documented on angiography after Absorb scaffold 
implantation. However, there have been no true comparative randomized data.
methods:  We assessed 501 patients treated with either Absorb (335 pts, 364 lesions) or Xience (EES) (166 pts, 182 lesions) in the 
ABSORB II randomized trial. Acute absolute recoil, assessed by quantitative coronary angiography, was defined as the difference between 
mean diameter of the last inflated balloon at the highest pressure and mean lumen diameter of the scaffold or stent immediately after 
expressed as a percentage.
results:  Out of 546 lesions treated in the randomized ABSORB II trial, 486 lesions were available for complete analysis of acute recoil. 
The nominal size of devices used (Absorb arm: 3.01± 0.31 vs. Xience arm: 3.05± 0.28mm, p=0.10) and the angiographic acute recoil 
measured immediately after the device implantation (Absorb arm: 0.19± 0.19 vs. Xience arm: 0.19± 0.18mm, p=0.85) were similar between 
2 treatment arms. The acute recoil were similar between the two treatment arms consistently in a subgroup of patients with a small 
reference diameter (< 2.57mm: Absorb arm: 0.21± 0.18 vs. 0.21± 0.16 mm, p=0.868) and in the patients with a high scaffold / artery ratio 
(ratio >1.0, Absorb arm: 0.21± 0.18 vs. Xience arm: 0.20± 0.18, p=0.405). In the multivariate analysis, (larger) obstruction minimum lumen 
diameter (OR:0.42, 95% CI:0.207 to 0.850, p=0.016) and non-symmetrical lumen stenosis assessed by angiography (OR:0.34, 95% CI: 
0.134 to 0.843, p=0.020) were protective for high acute recoil (>0.29 mm) while the device type was not a predictor of high acute recoil.
Conclusion:  There were no differences in acute recoil of device following implantation of Absorb BVS and Xience, and the device type 
was not a predictor of high acute recoil.
